Scientists have identified a way to develop a vaccine against Chlamydia trachomatis, the most prevalent sexually transmitted bacterial infection in the world.
Boffins identified plasmid-deficient derivatives of the Chlamydia trachomatis strains that when investigated in an animal model of genital tract infection, failed to cause disease.
The researchers now believe that this may serve as a vaccine against the disease.
The research was led by Toni Darville, MD, chief of the Division of Pediatric Infectious Diseases along with other scientists at Children's Hospital of Pittsburgh of UPMC. The results of the study are published in the Sept. 15 issue of the Journal of Immunology.
"This finding represents a major step forward in our work to eventually develop a vaccine against chlamydial disease," said Dr. Darville, senior author of the study and also a professor of pediatrics and microbiology/immunology at the University of Pittsburgh School of Medicine.
"If we can identify plasmid-deficient derivatives of the C. trachomatis strains that infect humans, they would have the potential to serve as a vaccine against this disease."
Symptoms of the infection are usually mild or absent, so, it can damage a woman's reproductive organs and cause irreversible damage, including infertility, before a woman ever recognizes a problem.
In this study, a plasmid-deficient strain derived from Chlamydia muridarum was introduced to mice. The mice became infected but did not develop the trademark signs of chlamydial disease, particularly damage to the oviduct, the tube that carries eggs from the ovaries, according to Catherine M. O'Connell, PhD, a researcher in Dr. Darville's laboratory and first author of the study.
"Not only did the mice not develop oviduct scarring after infection with the plasmid-deficient strain, we also found that the mice previously infected with these strains were protected against oviduct disease when later infected with fully virulent C. muridarum," Dr. O'Connell said.